Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

Clinical trial NCT02116777 · COMPLETED

Trial details

NCT number: NCT02116777
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Adult Solid Neoplasm Childhood Solid Neoplasm Recurrent Childhood Central Nervous System Neoplasm Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Malignant Solid Neoplasm Refractory Central Nervous System Neoplasm

Start date: 2014-05-16
Primary completion: 2018-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.